-
NHC Addresses Anti-Corruption Efforts in Pharmaceutical Industry Nationwide
•
The National Health Commission (NHC) convened a conference to address questions on the ongoing anti-corruption crackdown in the pharmaceutical industry, a campaign that spans across the nation. Last month, the NHC, along with eight other ministries, launched a one-year centralized rectification program aimed at tackling corruption within the medical industry.…
-
Pfizer’s Elrexfio Earns Accelerated FDA Approval for Relapsed/Refractory Multiple Myeloma
•
This week, Pfizer (NYSE: PFE) received an accelerated approval from the US Food and Drug Administration (FDA) for its bispecific antibody (BsAb) Elrexfio (elranatamab) as a treatment for relapsed or refractory multiple myeloma (r/rMM) in adults who have received at least four prior lines of therapy. The decision was based…
-
Novartis Acquires Chinook Therapeutics for $3.2 Billion, Eyes Kidney Disease Market
•
Switzerland-based pharmaceutical major Novartis (NYSE: NVS) has successfully completed the scheduled purchase of US-based kidney disease specialist Chinook Therapeutics (NASDAQ: KDNY) for a payment of $3.2 billion to its shareholders. An additional $300 million will be paid once regulatory milestones are achieved. This acquisition will enhance Novartis’s renal portfolio with…
-
Janssen’s Talvey Receives FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
•
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) announced last week that it received accelerated approval from the US Food and Drug Administration (FDA) for its first-in-class GPRC5D/CD3 bispecific antibody (BsAb), Talvey (talquetamab). This treatment is designated for adults with relapsed or refractory multiple myeloma (r/rMM) who have…
-
Novo Nordisk to Acquire Inversago Pharma in a Deal Valued Up to USD 1.1 Billion
•
Denmark’s leading pharmaceutical company, Novo Nordisk (NYSE: NVO), has reached an agreement to acquire Canada-based cardiometabolic disorder specialist Inversago Pharma by the end of the year, subject to regulatory approvals and other customary conditions. The acquisition deal could reach a total value of USD 1.1 billion if all development and…
-
Telix Pharmaceuticals and Grand Pharma Initiate Phase III Trial for Illucix in China
•
Australian biotechnology company Telix Pharmaceuticals Ltd (ASX: TLX) and its China market partner, Grand Pharmaceutical Group Limited (HKG: 0512), have announced the dosing of the first patient in a pivotal Phase III trial for TLX591-CDx (Illucix) in China. TLX591-CDx is a kit for the preparation of Gallium 68 (68Ga) PSMA-11,…
-
Mirxes Holding Company Receives FDA Breakthrough Device Designation for GASTROClea
•
Singapore-based RNA technology company, Mirxes Holding Company Ltd, which specializes in blood-based miRNA test kit products, has announced that it has received Breakthrough Device Designation (BDD) from the US FDA. This prestigious award marks the first time it has been given to a gastric cancer in vitro diagnostic (IVD) product…
-
China Unveils State Council Measures to Boost Foreign Direct Investment
•
The State Council of China has demonstrated its commitment to encouraging greater foreign investment by releasing a comprehensive set of Opinions aimed at optimizing the environment for Foreign Direct Investment (FDI) in the country. The measures are designed to foster a more conducive business climate and include: Support for R&D…
